BFM
CLLS

Boothbay Fund Management’s Cellectis CLLS Stock Holding History

Boothbay Fund Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,500
Closed -$236K – 759
2018
Q1 		$236K Buy
+7,500
New +$237K 0.03% 558

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Boothbay Fund Management's CLLS Position: Q2 2018 in Review

Boothbay Fund Management sold out of Cellectis (CLLS) in Q2 2018, closing a stake of 7,500 shares — an estimated $236K sold.

Boothbay Fund Management first reported a position in CLLS in Q1 2018 and held it in 1 quarter. The position peaked at $236K in Q1 2018. 86 funds tracked by Wall St. Rank hold CLLS as of Q2 2018.

  • Boothbay Fund Management reported no remaining Cellectis position as of Q2 2018 after selling out during the quarter.
  • Boothbay Fund Management sold 7,500 Cellectis shares in Q2 2018, an estimated $236K.
  • Boothbay Fund Management first reported a position in Cellectis in Q1 2018 and held it in 1 quarter.
  • Boothbay Fund Management's Cellectis position peaked at $236K in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Cellectis as of Q2 2018.

Based on Boothbay Fund Management's 13F filing for Q2 2018, filed 14 Aug 2018.